4DMT https://validator.w3.org/feed/docs/rss2.html Frank G. Holz, MD, FEBO, FARVO Home Careers Pipeline Contact Retinal Diseases Patients About Kim Maplestone An Song, PhD Calvin W. Roberts, MD Noriyuki Kasahara, MD, PhD Fred Kamal, PhD Wiley A. Chambers, MD David Kirn, MD David Kirn, MD Susannah Gray, MBA Nancy Miller-Rich Glenn P. Sblendorio Shawn Tomasello, MBA Charles Theuer, MD, PhD Jacob Chacko, MD, MBA John F. Milligan, PhD Scott Bizily, JD, PhD Theresa Janke Kristian Humer Chris Simms The gene therapy shift: A closer look at the science powering next-generation retinal treatments Katy Barglow, PhD ARVO 2025: Christine Kay, MD, shares interim results from the PRISM trial population extension cohort Prof. Sobha Sivaprasad DM, FRCS, FRCOphth 4D-150 maintains visual acuity in wet AMD at 2 years 4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy’s phase 3 plans CF Foundation adds to investment in 4DMT’s CF gene therapy 4DMT’s eye gene therapy cuts need for injections that treat diabetic macular edema A new approach to DME treatment First Patients Enrolled in 4DMT’s Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD Dhaval Desai, PharmD “Speed is survival”: Inside 4D Molecular Therapeutics bid to scale genetic medicine Dante Pieramici, MD Anat Loewenstein, MD, MHA Arshad M. Khanani, MD, MA, FASRS Patricio G. Schlottmann, MD 4DMT Company Updates Yuichiro Ogura, MD, PhD FDA grants RMAT designation to 4DMT for DME gene therapy 4DMT announces positive 52-week data from phase 2b cohort of PRISM wet AMD study 4D-150 Reduces Injection Burden in DME, Paving Way for FDA-Backed Phase 3 Julie Clark, MD Technology